Wednesday, 26 August 2026European Markets

ONWARD MEDICAL Stock Was Up By 10.95% Today

Loading stream...

(VIANEWS) - The Market ended the session with ONWARD MEDICAL (ONWD.BR) rising 10.95% to €2.33 on Wednesday while BEL 20 jumped 0.9% to €3,631.05.

ONWARD MEDICAL's last close was €2.10, 66.88% below its 52-week high of €6.34.

About ONWARD MEDICAL

Onward Medical N.V., a medical technology company, focuses on developing therapies for spinal cord injuries in the Netherlands and internationally. The company engages in developing ARC-EX, an external non-invasive platform that consists of a wearable stimulator and wireless programmer; and ARCIM, an implantable platform, which consists of an implantable pulse generator and lead that is placed near the spinal cord. It also engages in developing Up-LIFT Trial to evaluate the safety and effectiveness of non-invasive electrical spinal cord stimulation to treat upper extremity functional deficits with chronic tetraplegia. The company was founded in 2014 and is headquartered in Eindhoven, Netherlands.

Earnings Per Share

As for profitability, ONWARD MEDICAL has a trailing twelve months EPS of €-1.2.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -69.93%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ONWARD MEDICAL's stock is considered to be overbought (>=80).

Revenue Growth

Year-on-year quarterly revenue growth declined by 3.6%, now sitting on 2.11M for the twelve trailing months.

Yearly Top and Bottom Value

ONWARD MEDICAL's stock is valued at €2.33 at 21:37 EST, way below its 52-week high of €6.34 and way higher than its 52-week low of €1.85.

More news about ONWARD MEDICAL (ONWD.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com